Article
Oncology
Kazuhito Ueki, Yukinori Matsuo, Atsuya Takeda, Satoshi Morita, Masataka Taguri, Noriko Kishi, Hideki Hanazawa, Yuichiro Tsurugai, Takashi Mizowaki
Summary: The study aimed to assess the impact of local recurrence (LR) on cause-specific death (CSD) in non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). A dynamic prediction model incorporating LR as a time-dependent covariate was used. The findings showed that LR significantly influenced subsequent CSD, supporting strategies to improve local control.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Simona Mega, Michele Fiore, Myriam Carpenito, Maria Laura Novembre, Marianna Miele, Luca Eolo Trodella, Francesco Grigioni, Edy Ippolito, Sara Ramella
Summary: This study evaluates early changes in cardiac function after chemoradiotherapy in patients with non-small-cell lung cancer. The results indicate that global longitudinal strain and ejection fraction progressively decrease after treatment, with a significant correlation. Additionally, some patients experience cardiac arrhythmias after treatment.
Article
Oncology
Subaru Sawayanagi, Hideomi Yamashita, Yuki Nozawa, Ryosuke Takenaka, Yosuke Miki, Kosuke Morishima, Hiroyuki Ueno, Takeshi Ohta, Atsuto Katano
Summary: This study aimed to identify prognostic factors and establish predictive models for survival outcomes in non-metastatic NSCLC patients treated with SBRT. The study found one radiomic factor and one predictive model that showed significant impact on overall survival and accurately estimated survival time.
Article
Oncology
Karen Huang, Sharan Prasad, Sung Jun Ma, Han Yu, Austin J. J. Iovoli, Mark K. K. Farrugia, Elizabeth U. U. Dexter, Todd L. L. Demmy, Nadia K. K. Malik, Anurag K. K. Singh
Summary: This observational cohort study found that pretreatment neutrophil-lymphocyte ratio (NLR) is an independent predictor for survival outcomes of early-stage NSCLC patients treated with single fraction SBRT. The study showed that NLR, as a continuous variable, is independently associated with overall survival and progression-free survival, as well as disease-free survival.
Article
Oncology
James E. Han, Shaakir Hasan, J. Isabelle Choi, Robert H. Press, Charles B. Simone
Summary: The timing of surgery following neoadjuvant chemoradiation has a significant impact on the overall survival of patients with locally advanced non-small-cell lung cancer. Surgery performed within 7 weeks after chemoradiation completion is associated with better survival outcomes, while delaying surgery beyond 7 weeks is correlated with poorer survival. Additionally, early surgery within 66 days post-chemoradiation is associated with improved survival outcomes. Higher neoadjuvant radiotherapy doses may facilitate surgery within the optimal 7-week interval and minimize risks of complications.
Article
Oncology
Saber A. Amin, Morshed Alam, Michael J. Baine, Jane L. Meza, Nathan R. Bennion, Chi Zhang, Ibur Rahman, Chi Lin
Summary: The study investigated the impact of SBRT on the overall survival of early-stage NSCLC patients, showing that SBRT was associated with improved overall survival. The magnitude of the impact of SBRT on overall survival was found to increase in patients with advanced age, higher T stages, higher comorbidity scores, and more recent treatment eras.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Yongmei Liu, Weili Wang, Kevin Shiue, Huan Yao, Alberto Cerra-Franco, Ronald H. Shapiro, Ke Colin Huang, Douglas Vile, Mark Langer, Gordon Watson, Greg Bartlett, Huisi Ai, Francis Sheski, Jian-Yue Jin, Rich Zellars, Pingfu Fu, Tim Lautenschlaeger, Feng-Ming (Spring) Kong
Summary: This study investigated risk factors for radiation pneumonitis (RP) in NSCLC patients undergoing SBRT, finding that factors such as respiratory comorbidity history, previous thoracic radiation, and right lung location were significantly associated with RP2. A model combining clinical and dosimetric factors showed high predictive accuracy, suggesting that limiting mean lung dose can reduce lung toxicity risk.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Suli Zhang, Qian Sun, Feng Cai, Hui Li, Yufu Zhou
Summary: This review analyzes treatment strategies and prognostic factors for patients with oligometastatic non-small cell lung cancer (OM-NSCLC), with a focus on the importance of local ablation therapy (LAT) as a significant treatment component.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia
Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.
Article
Oncology
Zhouguang Hui, Yu Men, Chen Hu, Jingjing Kang, Xin Sun, Nan Bi, Zongmei Zhou, Jun Liang, Jima Lv, Qinfu Feng, Zefen Xiao, Dongfu Chen, Yan Wang, Junling Li, Jie Wang, Shugeng Gao, Luhua Wang, Jie He
Summary: The study evaluated the impact of postoperative radiotherapy (PORT) on survival and safety in patients with pIIIA-N2 non-small cell lung cancer. The results showed that PORT did not improve disease-free survival but helped reduce local recurrence.
Article
Oncology
Nasser K. Altorki, Timothy E. McGraw, Alain C. Borczuk, Ashish Saxena, Jeffrey L. Port, Brendon M. Stiles, Benjamin E. Lee, Nicholas J. Sanfilippo, Ronald J. Scheff, Bradley B. Pua, James F. Gruden, Paul J. Christos, Cathy Spinelli, Joyce Gakuria, Manik Uppal, Bhavneet Binder, Olivier Elemento, Karla Ballman, Silvia C. Formenti
Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.
Article
Oncology
Rui Zhou, Bo Qiu, Mai Xiong, Yimei Liu, Kangqiang Peng, Yifeng Luo, Daquan Wang, Fangjie Liu, Naibin Chen, Jinyu Guo, Jun Zhang, Xiaoyan Huang, Yuming Rong, Hui Liu
Summary: This study aimed to investigate the safety and efficacy of hypofractionated radiation therapy combined with concurrent chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. The results showed that this treatment regimen could provide satisfactory local control and survival outcomes, with moderate radiation-induced toxicity.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Janna Berg, Christina Ramberg, Jon Olav Sulheim Haugstvedt, May-Bente Bengtson, Anne-Marie Gabrielsen, Odd Terje Brustugun, Ann Rita Halvorsen, Aslaug Helland
Summary: This study investigated changes in pulmonary function, symptoms, and radiological signs of pneumonitis in patients receiving stereotactic body radiation therapy for early-stage non-small cell lung cancer. Symptomatic radiation pneumonitis occurred in 18% of patients, while asymptomatic pneumonitis was observed in 39% based on radiology. Early decreases in FEV1 and DLCO may indicate the development of symptomatic radiation pneumonitis, which could be predicted by doses to critical lung volumes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Xiaofeng Wang, Hui Bai, Miaomiao Gao, Yong Guan, Lu Yu, Junyi Li, Yang Dong, Yongchun Song, Zhen Tao, Maobin Meng, Zhiqiang Wu, Lujun Zhao, Zhiyong Yuan
Summary: This study evaluated the impact of estimated dose of radiation to immune cells (EDRIC) in early-stage non-small cell lung cancer (ES-NSCLC). The results showed that EDRIC was an independent predictor of cancer-specific survival (CSS) and distant metastasis-free survival (DMFS), and it was influenced by tumor volume and location. Further research is needed to explore the feasibility of achieving lower EDRIC while maintaining sufficient tumor coverage during radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Clinical Neurology
Matt Lechner, Yoko Takahashi, Mario Turri-Zanoni, Marco Ferrari, Jacklyn Liu, Nicholas Counsell, Davide Mattavelli, Vittorio Rampinelli, William Vermi, Davide Lombardi, Rami Saade, Ki Wan Park, Volker H. Schartinger, Alessandro Franchi, Carla Facco, Fausto Sessa, Simonetta Battocchio, Tim R. Fenton, Francis M. Vaz, Paul O'Flynn, David Howard, Paul Stimpson, Simon Wang, S. Alam Hannan, Samit Unadkat, Jonathan Hughes, Raghav Dwivedi, Cillian T. Forde, Premjit Randhawa, Simon Gane, Jonathan Joseph, Peter J. Andrews, Manas Dave, Jason C. Fleming, David Thomson, Tianyu Zhu, Andrew Teschendorff, Gary Royle, Christopher Steele, Joaquin E. Jimenez, Jan Laco, Eric W. Wang, Carl Snyderman, Peter D. Lacy, Robbie Woods, James P. O'Neill, Anirudh Saraswathula, Raman Preet Kaur, Tianna Zhao, Murugappan Ramanathan, Gary L. Gallia, Nyall R. London, Quynh-Thu Le, Robert B. West, Zara M. Patel, Jayakar V. Nayak, Peter H. Hwang, Mario Hermsen, Jose Llorente, Fabio Facchetti, Piero Nicolai, Paolo Bossi, Paolo Castelnuovo, Amrita Jay, Dawn Carnell, Martin D. Forster, Diana M. Bell, Valerie J. Lund, Ehab Y. Hanna
Summary: This study retrospectively analyzed clinical data from 505 cases of sinonasal mucosal melanoma (SNMM). It found that further stratifying the T3 stage by sinus involvement has a high predictive value for prognosis. Adjuvant radiotherapy can improve survival rates, and immune checkpoint inhibitors show potential benefits for the treatment of recurrent, persistent, or metastatic disease.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
(2023)
Review
Oncology
Tiuri E. Kroese, Peter S. N. van Rossum, Magnus Nilsson, Florian Lordick, Elizabeth C. Smyth, Riccardo Rosati, Philippe Nafteux, Domenico D'Ugo, M. Asif Chaudry, Wojciech Polkowkski, Franco Roviello, Ines Gockel, Piotr Kolodziejczyk, Karin Haustermans, Matthias Guckenberger, Marianne Nordsmark, Maria A. Hawkins, Andres Cervantes, Tania Fleitas, Eric van Cutsem, Markus Moehler, Anna D. Wagner, Hanneke W. M. van Laarhoven, Richard van Hillegersberg
Summary: Currently, there is a lack of uniform definition and treatment for oligometastatic esophagogastric cancer. The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to develop a multidisciplinary European consensus statement to improve outcomes for these patients.
Letter
Otorhinolaryngology
Matt Lechner, Jacklyn Liu, Nicholas Counsell, David Gillespie, Deepak Chandrasekharan, Ngan Hong Ta, Kiran Jumani, Raj Gupta, John Rocke, Claire Williams, Abigail Tetteh, Rajesh Amnolsingh, Sadie Khwaja, Rachel L. Batterham, Carol H. Yan, Thomas A. Treibel, James C. Moon, Jane Woods, Ria Brunton, Jim Boardman, Matthew Hatter, Mohamed Abdelwahab, F. Christopher Holsinger, Robson Capasso, Jayakar V. Nayak, Peter H. Hwang, Zara M. Patel, Santdeep Paun, Nicholas Eynon-Lewis, B. Nirmal Kumar, Samuel Jayaraj, Claire Hopkins, Carl Philpott, Valerie J. Lund
Article
Hematology
Valeria Fiaccadori, Anouk Neven, Catherine Fortpied, Igor Aurer, Marc Andre, Massimo Federico, Nicholas Counsell, Elizabeth H. Phillips, Laura Clifton-Hadley, Sally F. Barrington, Timothy Illidge, John Radford, John M. M. Raemaekers
Summary: The H10 and RAPID trials compared combined modality treatment (CMT) with chemotherapy (C) in limited-stage Hodgkin lymphoma (HL) with negative early positron emission tomography (ePETneg). The results showed that omitting radiotherapy (RT) in ePETneg HL resulted in more early relapses, while RT significantly reduced the risk of early relapses in both trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
T. Bosse, C. L. Creutzberg, E. J. Crosbie, K. Han, N. Horeweg, A. Leary, J. R. Kroep, J. N. McAlpine, M. E. Powell, F. Blanc-Durand, M. de Bruyn, D. N. Church, V. H. Koelzer, S. Kommoss, N. Singh, A. Bardet, N. Counsell, H. Putter, D. Tu, R. Edmondson, C. Gordon, J. Ledermann, P. Morice, H. MacKay, H. Nijman, R. A. Nout, V. T. H. B. M. Smit, H. White, J. Alexandre, S. M. de Boer, I Boere, R. Cooper, J. L. Ethier, J. S. Frenel, J. McGrane, A. Taylor, S. Welch, A. M. Westermann, H. Dijcker-van der Linden, L. Farrelly, A. Feeney, M. Kaya, W. Liu, A. Melis, F. Ngadjeua-Tchouatieu, W. Parulekar, K. Verhoeven-Adema, RAINBO Res Consortium
Summary: The RAINBO program aims to investigate molecular class-directed adjuvant treatment strategies for endometrial cancer, with the goal of improving clinical outcomes and reducing toxicity. It consists of four international clinical trials and an overarching research program to advance knowledge of predictive and prognostic markers.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Letter
Otorhinolaryngology
Matt Lechner, Jacklyn Liu, Nicholas Counsell, Carol. H. H. Yan, Santdeep Paun, Nicholas Eynon-Lewis, Liam Sutton, Samuel Jayaraj, Rachel L. Batterham, Claire Hopkins, Carl Philpott, Valerie J. Lund, Matthew Hatter, Mohamed Abdelwahab, F. Christopher Holsinger, Robson Capasso, Jayakar. V. V. Nayak, Peter. H. H. Hwang, Zara. M. M. Patel
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
(2023)
Article
Oncology
M. Robinson, R. Muirhead, D. R. Mcgowan, K. -Y. Chu, C. Jacobs, M. A. Hawkins
Summary: The definition of active pelvic bone marrow as FDG uptake greater than the mean of the whole structure can represent underlying cell physiology. This study supports the feasibility of atlas-based approaches published in the literature to contour active bone marrow based on the current definition.
Article
Oncology
Tiuri E. Kroese, Hanneke W. M. van Laarhoven, Sebastian F. Schoppman, Pieter R. A. J. Deseyne, Eric van Cutsem., Karin Haustermans., Philippe. Nafteux, Melissa Thomas, Radka Obermannova, Hanna R. Mortensen, Marianne Nordsmark, Per Pfeiffer, Anneli Elme, Antoine Adenis, Guillaume Piessen, Christiane J. Bruns, Florian Lordick, Ines Gockel, Markus Moehler, Cihan Gani, Theodore Liakakos, John Reynolds, Alessio G. Morganti, Riccardo Rosati, Carlo Castoro, Francesco Cellini, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Jolanda van Dieren, Marieke Vollebergh, Johanna W. van Sandick, Paul Jeene, Christel T. Muijs, Marije Slingerland, Francine E. M. Voncken, Henk Hartgrink, Geert-Jan Creemers, Maurice J. C. van der Sangen, Grard Nieuwenhuijzen, Maaike Berbee, Marcel Verheij, Bas Wijnhoven, Laurens V. Beerepoot, Nadia H. Mohammad, Stella Mook, Jelle P. Ruurda, Piotr Kolodziejczyk, Wojciech P. Polkowski, Lucjan Wyrwicz, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Andres Cervantes, Magnus Nilsson, Stefan Monig, Anna D. Wagner, Matthias Guckenberger, Ewen A. Griffiths, Elizabeth Smyth, George B. Hanna, Sheraz Markar, M. Asif Chaudry, Maria A. Hawkins, Edward Cheong, Richard van Hillegersberg, Peter S. N. van Rossum
Summary: This study aimed to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophago-gastric cancer. Through a series of discussions and expert evaluations, a consensus was reached, which can be used for future research in clinical trials.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Michael D. Chuong, Christopher J. Anker, Michael H. Buckstein, Maria A. Hawkins, Jordan Kharofa, Ann C. Raldow, Nina N. Sanford, Andrzej Wojcieszysnki, Jeffrey R. Olsen
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Gastroenterology & Hepatology
Simon M. Rushbrook, Timothy James Kendall, Yoh Zen, Raneem Albazaz, Prakash Manoharan, Stephen P. Pereira, Richard Sturgess, Brian R. Davidson, Hassan Z. Malik, Derek Manas, Nigel Heaton, K. Raj Prasad, John Bridgewater, Juan W. Valle, Rebecca Goody, Maria Hawkins, Wendy Prentice, Helen Morement, Martine Walmsley, Shahid A. Khan
Summary: These guidelines commissioned by the British Society of Gastroenterology liver section provide guidance for the diagnosis and management of cholangiocarcinoma (CCA). The writing committee includes a multidisciplinary team of experts and patient/public representatives. Quality of evidence is evaluated using the AGREE II format. The recommendations are meant to guide rather than serve as strict references.
Editorial Material
Oncology
Krishan R. Jethwa, William S. Harmsen, Maria A. Hawkins, Hyun Kim, Nina N. Sanford, Andrzej P. Wojcieszynski, Jeffrey R. Olsen
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Sean M. O'Cathail, Richard Adams, Maria A. Hawkins, David Sebag-Montefiore, Corrie A. M. Marijnen, Emmanouil Fokas
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Meeting Abstract
Oncology
H. T. Huang, M. A. Hawkins, J. D. Fenwick, M. G. Nix
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Meeting Abstract
Oncology
S. Mukherjee, S. Lord, R. Harman, D. McIntosh, A. Ooms, M. Parkes, G. Radhakrishna, P. H. Shaw, M. A. Hawkins
ANNALS OF ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
P. Lally, N. Miller, A. Roberts, R. J. Beeken, D. M. Greenfield, H. W. W. Potts, N. Counsell, N. Latimer, C. Thomas, L. Smith, J. Gath, F. Kennedy, C. Martin, L. Wyld, A. Fisher
Summary: This trial aims to pilot a theory-driven, app-based intervention that promotes brisk walking among people living with and beyond cancer. The study will investigate the feasibility and acceptability of the intervention and collect data to inform a larger future study.
PILOT AND FEASIBILITY STUDIES
(2022)